Judith Klimovsky
Director/Board Member at BIO-TECHNE CORPORATION
Net worth: 3 M $ as of 2024-03-30
Judith Klimovsky active positions
| Companies | Position | Start | End |
|---|---|---|---|
| GENMAB A/S | Corporate Officer/Principal | 2017-02-08 | - |
| BIO-TECHNE CORPORATION | Director/Board Member | 2024-04-23 | - |
| Independent Dir/Board Member | 2024-04-23 | - |
Career history of Judith Klimovsky
Former positions of Judith Klimovsky
| Companies | Position | Start | End |
|---|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Director/Board Member | 2018-12-19 | 2024-02-22 |
| NOVARTIS AG | Corporate Officer/Principal | 2009-04-30 | 2017-01-31 |
Novartis Pharma AG
 Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 2008-12-31 | 2016-12-31 |
Training of Judith Klimovsky
| University of Buenos Aires School of Medicine | Doctorate Degree |
Statistics
International
| United States | 3 |
| Switzerland | 3 |
| Denmark | 2 |
Operational
| Corporate Officer/Principal | 3 |
| Director/Board Member | 2 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| BIO-TECHNE CORPORATION | Health Technology |
| NOVARTIS AG | Health Technology |
| GENMAB A/S | Health Technology |
| Private companies | 2 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Judith Klimovsky
- Experience
